2016 冠状动脉旁路移植术围术期抗血小板治疗专家共识

2016-01-30 中华胸心血管外科杂志.2016,32(1):1-8.

抗血小板治疗是冠状动脉旁路移植术(CABG)围术期最重要的药物治疗之一,抗血小板药物对于CABG改善患者旁路血管通畅率及降低围术期心梗发生率的积极作用已有广泛共识。近年来大量前瞻性临床试验使人们对抗血板治疗的观念不断变化,新的抗血小板药物层出不穷,各种血小板功能检测的方法逐步应用于临床。在这一背景下我国心脏外科医师对于围术期抗血小板治疗的理念亟待更新。我们全面回顾近年来与抗血小板治疗相关的临床试验

中文标题:

2016 冠状动脉旁路移植术围术期抗血小板治疗专家共识

发布机构:

发布日期:

2016-01-30

简要介绍:

抗血小板治疗是冠状动脉旁路移植术(CABG)围术期最重要的药物治疗之一,抗血小板药物对于CABG改善患者旁路血管通畅率及降低围术期心梗发生率的积极作用已有广泛共识。近年来大量前瞻性临床试验使人们对抗血板治疗的观念不断变化,新的抗血小板药物层出不穷,各种血小板功能检测的方法逐步应用于临床。在这一背景下我国心脏外科医师对于围术期抗血小板治疗的理念亟待更新。我们全面回顾近年来与抗血小板治疗相关的临床试验及文献证据,结合美国及欧洲的最新权威指南,充分考虑我国患者的特点及我国外科医师的诊疗习惯撰写了本专家共识,作为CABG围术期抗血小板治疗的临床实践参考。


共识从以下9个方面进行介绍:

1.常用抗血小板药物
2.血小板功能检测
3.药物基因组学与抗血小板药物
4.围术期高出血或缺血风险患者的分类
5.术前服用抗血小板药物的处理原则
6.心脏手术后的抗血小板药物
7.对在某些特定临床情况下使用抗血小板药物的患者管理
8.从不同学科的角度考虑抗血小板药物的使用

相关资料下载:
[AttachmentFileName(sort=100, fileName=2016 冠状动脉旁路移植术围术期抗血小板治疗专家共识)] GetToolGuiderByIdResponse(projectId=1, id=c01ca1c0012e19c1, title=2016 冠状动脉旁路移植术围术期抗血小板治疗专家共识, enTitle=, guiderFrom=中华胸心血管外科杂志.2016,32(1):1-8., authorId=null, author=, summary=抗血小板治疗是冠状动脉旁路移植术(CABG)围术期最重要的药物治疗之一,抗血小板药物对于CABG改善患者旁路血管通畅率及降低围术期心梗发生率的积极作用已有广泛共识。近年来大量前瞻性临床试验使人们对抗血板治疗的观念不断变化,新的抗血小板药物层出不穷,各种血小板功能检测的方法逐步应用于临床。在这一背景下我国心脏外科医师对于围术期抗血小板治疗的理念亟待更新。我们全面回顾近年来与抗血小板治疗相关的临床试验, cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Sat Jan 30 00:00:00 CST 2016, originalUrl=, linkOutUrl=, content=抗血小板治疗是冠状动脉旁路移植术(CABG)围术期最重要的药物治疗之一,抗血小板药物对于CABG改善患者旁路血管通畅率及降低围术期心梗发生率的积极作用已有广泛共识。近年来大量前瞻性临床试验使人们对抗血板治疗的观念不断变化,新的抗血小板药物层出不穷,各种血小板功能检测的方法逐步应用于临床。在这一背景下我国心脏外科医师对于围术期抗血小板治疗的理念亟待更新。我们全面回顾近年来与抗血小板治疗相关的临床试验及文献证据,结合美国及欧洲的最新权威指南,充分考虑我国患者的特点及我国外科医师的诊疗习惯撰写了本专家共识,作为CABG围术期抗血小板治疗的临床实践参考。<div><br></div><div>共识从以下9个方面进行介绍:<br> <br>1.常用抗血小板药物<div>2.血小板功能检测<div>3.药物基因组学与抗血小板药物</div><div>4.围术期高出血或缺血风险患者的分类</div><div>5.术前服用抗血小板药物的处理原则</div><div>6.心脏手术后的抗血小板药物</div><div>7.对在某些特定临床情况下使用抗血小板药物的患者管理</div><div>8.从不同学科的角度考虑抗血小板药物的使用</div><div>9.展望<br><br> <span style="font-weight: bold;">制定者:</span> <div>中国胸心外科相关专家组(统称)</div> <div>冠状动脉旁路移植术围术期抗血小板治疗共识专家组<br> <br> 拓展指南:<strong>与<font color="red">抗血小板治疗</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=81ae41c001102845" title="2014 WHF专家共识声明:东亚ACS或接受PCI治疗患者的抗血小板治疗" target="_blank">2014 WHF专家共识声明:东亚ACS或接受PCI治疗患者的抗血小板治疗</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=598141c0010895c5" title="短暂性脑缺血发作与轻型卒中抗血小板治疗中国专家共识(2014年)" target="_blank">短暂性脑缺血发作与轻型卒中抗血小板治疗中国专家共识(2014年)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=849bd1c000969296" title="2013 抗血小板治疗中国专家共识" target="_blank">2013 抗血小板治疗中国专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=fc2151c00095ae95" title="2012 马来西亚胃肠病、肝病学会和心脏学会关于抗血小板治疗和质子泵抑制剂在预防胃肠道出血中的共识" target="_blank">2012 马来西亚胃肠病、肝病学会和心脏学会关于抗血小板治疗和质子泵抑制剂在预防胃肠道出血中的共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=f43de1c000928314" title="2012 CCS加拿大心血管学会应用抗血小板治疗指南(更新版)" target="_blank">2012 CCS加拿大心血管学会应用抗血小板治疗指南(更新版)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E6%8A%97%E8%A1%80%E5%B0%8F%E6%9D%BF%E6%B2%BB%E7%96%97" target="_blank">有关抗血小板治疗更多指南</a></ul></div></div></div></div>, tagList=[TagDto(tagId=9761, tagName=冠状动脉), TagDto(tagId=100889, tagName=旁路移植术), TagDto(tagId=2733, tagName=抗血小板治疗)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=24, categoryName=胸心外科, tenant=100), CategoryDto(categoryId=43, categoryName=冠心病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6091, appHits=236, showAppHits=15, pcHits=4341, showPcHits=2346, likes=138, shares=4, comments=4, approvalStatus=1, publishedTime=Tue Sep 06 12:04:38 CST 2016, publishedTimeString=2016-01-30, pcVisible=1, appVisible=1, editorId=5295957, editor=lili, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=lili, createdTime=Tue Sep 06 12:04:38 CST 2016, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 06:56:19 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2016 冠状动脉旁路移植术围术期抗血小板治疗专家共识)])
2016 冠状动脉旁路移植术围术期抗血小板治疗专家共识
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2189090, encodeId=ab57218909086, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a1e9026319, createdName=ms5000001674210645, createdTime=Sat Feb 24 13:53:03 CST 2024, time=2024-02-24, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=903165, encodeId=b4f6903165ee, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01ad9749, createdName=archazrael, createdTime=Sat Nov 28 23:09:37 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=123144, encodeId=efa61231449d, content=很好,不错,以后会多学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sun Sep 11 21:51:00 CST 2016, time=2016-09-11, status=1, ipAttribution=)]
    2024-02-24 ms5000001674210645 来自辽宁省

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2189090, encodeId=ab57218909086, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a1e9026319, createdName=ms5000001674210645, createdTime=Sat Feb 24 13:53:03 CST 2024, time=2024-02-24, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=903165, encodeId=b4f6903165ee, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01ad9749, createdName=archazrael, createdTime=Sat Nov 28 23:09:37 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=123144, encodeId=efa61231449d, content=很好,不错,以后会多学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sun Sep 11 21:51:00 CST 2016, time=2016-09-11, status=1, ipAttribution=)]
    2020-11-28 archazrael

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2189090, encodeId=ab57218909086, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=11, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a1e9026319, createdName=ms5000001674210645, createdTime=Sat Feb 24 13:53:03 CST 2024, time=2024-02-24, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=903165, encodeId=b4f6903165ee, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01ad9749, createdName=archazrael, createdTime=Sat Nov 28 23:09:37 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=123144, encodeId=efa61231449d, content=很好,不错,以后会多学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Sun Sep 11 21:51:00 CST 2016, time=2016-09-11, status=1, ipAttribution=)]
    2016-09-11 李东泽

    很好,不错,以后会多学习

    0